053: Evolution of antiplatelet therapy compliance during the first year after percutaneous coronary intervention: a 100 patients monocentric cohort

Abstract

Non compliance to dual antiplatelet therapy (DAT) after PCI is associated to a higher cardiovascular mortality. Previous studies about DAT discontinuation only analysed non compliance during short periods, generally less than three months. The purpose of this monocentric prospective study was to analyse DAT discontinuation during a one year follow-up in real-life patients after PCI. We prospectively included 103 consecutive patients who underwent PCI. They underwent a phone questionnaire focusing on DAT compliance every three months on a one year follow-up. Three groups of patients were defined according to compliance WHO (World Health Organization) definition: DAT oversight more than once a week, self-willed DAT discontinuation and good adherers. A total of 100 patients had complete data. Global non compliance to DAT (oversight and discontinuation) was about 33% at twelve months. Twenty seven percent patients forgot DAT more than once a week at one year. More than 50% of DAT oversight occurred within the first month. Self-willed DAT discontinuation occurred in 13% cases, with a progressive increase on the first 12 months, mainly explained by weariness or treatment side effects. Global DAT non compliance at one year was about 33% cases. There were two profiles of DAT non compliance: oversight, occurring almost within the first month and self-willed DAT discontinuation which progressively increased during the first year. Therapeutic education seems to be pivotal to prevent both behaviours.